Control of vector-borne infectious diseases by human immunity against α-Gal.
a Center for Infection and Immunity of Lille (CIIL), INSERM U1019 - CNRS UMR 8204 , Université Lille Nord de France, Institut Pasteur de Lille , Lille , France.
Alejandro
A
Cabezas Cruz
b Institute of Parasitology , Biology Centre of the Academy of Sciences of the Czech Republic , České Budějovice , Czech Republic.|c Department of Virology , Veterinary Research Institute , Brno , Czech Republic.
James J
JJ
Valdés
d SaBio , Instituto de Investigación de Recursos Cinegéticos, IREC-CSIC-UCLM-JCCM , Ciudad Real , Spain.|e Department of Veterinary Pathobiology, Center for Veterinary Health Sciences , Oklahoma State University , Stillwater , OK , USA.
José
J
de la Fuente
D000818:Animals; D000906:Antibodies / Q000276:immunology*; D001419:Bacteria / Q000276:immunology*; D003141:Communicable Diseases / Q000276:immunology / Q000628:therapy* / Q000635:transmission; D004187:Disaccharides / Q000276:immunology*; D018562:Disease Transmission, Infectious / Q000517:prevention & control*; D004199:Disease Vectors; D019143:Evolution, Molecular; D054884:Host-Pathogen Interactions; D006801:Humans; D019936:Probiotics / Q000627:therapeutic use*; D014612:Vaccines / Q000276:immunology / Q000627:therapeutic use*
D000906:Antibodies; D004187:Disaccharides; D014612:Vaccines; C055075:galactosyl-(1-3)galactose
Microbiota; probiotics; vaccine; vector-borne diseases; α-Gal